INVO Bioscience Inc (INVO)
0.8401
-0.03
(-3.33%)
USD |
NASDAQ |
Jun 28, 16:00
0.8575
+0.02
(+2.07%)
After-Hours: 20:00
INVO Bioscience SG&A Expense (Annual): 7.486M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 7.486M |
| December 31, 2022 | 9.977M |
| December 31, 2021 | 9.015M |
| December 31, 2020 | 6.065M |
| December 31, 2019 | 3.129M |
| December 31, 2018 | 3.038M |
| December 31, 2017 | 0.8706M |
| December 31, 2016 | 2.146M |
| December 31, 2015 | 0.599M |
| Date | Value |
|---|---|
| December 31, 2014 | 1.690M |
| December 31, 2013 | 0.6217M |
| December 31, 2012 | 0.5878M |
| December 31, 2011 | 0.7567M |
| December 31, 2010 | 1.561M |
| December 31, 2009 | 1.857M |
| December 31, 2008 | 1.838M |
| December 31, 2007 | 0.0435M |
| December 31, 2006 | 0.0076M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
3.129M
Minimum
2019
9.977M
Maximum
2022
7.134M
Average
7.486M
Median
2023
SG&A Expense (Annual) Benchmarks
| Abbott Laboratories | 10.95B |
| Perspective Therapeutics Inc | 21.06M |
| Xtant Medical Holdings Inc | 64.29M |
| Asensus Surgical Inc | 36.08M |
| Catheter Precision Inc | 17.12M |